The recommended treatment options for patients with HER2-positive breast cancer are: trastuzumab in combination with paclitaxel (first-line); capecitabine (including in combination with lapatinib) or vinorelbine (including trastuzumab when there is evidence of progression in the central nervous system) (second-line); and vinorelbine or capecitabine or trastuzumab (third-line) [16]. Here, ERBB2 is linked to breast carcinoma.